Previous 10 | Next 10 |
2023-12-11 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Veru, Kodiak S...
BMF-219 demonstrated early signs of clinical activity and ability to achieve durable and sustained complete responses (CRs) with minimal residual disease negativity (MRD-neg) in acute myeloid leukemia (AML) patients Pharmacodynamic data further supports the mechanism of action of BMF-219 as a...
2023-12-11 08:27:31 ET Losers: Cogent Biosciences ( COGT ) -31% . announces positive data from ongoing phase 2 APEX trial evaluating Bezuclastinib in patients . Purple Biotech Ltd ( PPBT ) -16% . Sphere 3D Corp ( ANY ) -14% . FLJ Group Ltd ( F...
At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%. To date, the dose escalation portion has shown after on...
2023-12-08 16:43:19 ET Gainers: IGM Biosciences, Inc. ( IGMS ) +9% . EF Hutton Acquisition Corporation I ( EFHT ) +6% . Biomea Fusion ( BMEA ) +5% . Larimar Therapeutics ( LRMR ) +2% . First Solar ( FSLR ) +1% . Losers: L...
2023-12-08 13:13:33 ET More on Biomea Fusion Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells Biomea stock tumbles in wake of Phase 2 data for diabetes drug Biomea Fusion spikes after mid-stage data for diabetes candidate Seeking Alpha’s ...
2023-12-08 12:48:05 ET More on Biomea Fusion Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells Biomea Fusion spikes after mid-stage data for diabetes candidate Seeking Alpha’s Quant Rating on Biomea Fusion Historical earnings data for Biom...
2023-12-08 10:00:17 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Bluebird bio, ...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes At Week 26, 22 weeks after the last dose of BMF-219, participants in the 100 mg QD (without food) cohort saw an improved placebo adjusted mean re...
2023-12-07 12:09:15 ET More on Biomea Fusion Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells Seeking Alpha’s Quant Rating on Biomea Fusion Historical earnings data for Biomea Fusion Financial information for Biomea Fusion For fur...
News, Short Squeeze, Breakout and More Instantly...
Biomea Fusion Inc. Company Name:
BMEA Stock Symbol:
NASDAQ Market:
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases a...
2024-05-09 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healt...